Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical determinants, diagnostic complexity, and molecular heterogeneity in NF1-associated and sporadic malignant peripheral nerve sheath tumors: A 25-year referral-center cohort.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Myxoid neoplasms with MAP3K kinase fusion: a study of 39 cases.

Histopathology·2026
Same author

Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.

Journal of medical economics·2026
Same author

MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.

Nature communications·2026
Same author

Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.

EClinicalMedicine·2026
Same author

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.

Cancer research communications·2026

Related Experiment Video

Updated: Sep 7, 2025

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.0K

CIC-DUX4 sarcomas.

Mehdi Brahmi1,2, Hélène Vanacker1,2, Nicolas Macagno1,3

  • 1Centre Léon Bérard, 28 rue Laennec.

Current Opinion in Oncology
|June 22, 2022
PubMed
Summary

CIC-DUX4 sarcoma (CDS) is a rare, aggressive cancer in young adults. Despite treatment, outcomes remain poor, highlighting the need for further biological research and clinical trials.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.8K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.5K

Related Experiment Videos

Last Updated: Sep 7, 2025

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.0K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.8K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.5K

Area of Science:

  • Oncology
  • Molecular Pathology
  • Sarcoma Research

Background:

  • CIC-DUX4 sarcoma (CDS) is a rare, high-grade undifferentiated round cell sarcoma.
  • It affects young adults, often presenting with advanced disease and lung metastasis.
  • CDS is characterized by the CIC::DUX4 translocation, leading to ETV4 overexpression.

Purpose of the Study:

  • To review recent advancements in the molecular characterization of CDS.
  • To discuss the underlying biology of CDS.
  • To explore current and future therapeutic strategies for CDS.

Main Methods:

  • Review of recent scientific literature on CIC-DUX4 sarcoma.
  • Analysis of molecular characteristics and biological pathways.
  • Evaluation of current treatment approaches and future therapeutic prospects.

Main Results:

  • CDS exhibits an aggressive clinical course with a poor prognosis, often worse than Ewing sarcoma.
  • There is no current consensus on optimal treatment, with an Ewing-like approach often used.
  • Combination regimens with anthracyclines and alkylating agents are favored when feasible.

Conclusions:

  • CIC-DUX4 sarcoma demonstrates a poor prognosis irrespective of treatment.
  • Further biological studies are crucial for a better understanding of the disease.
  • Enrollment in clinical trials and prospective registries is strongly recommended.